SEC Comment Letter 0000000000-25-000439 to BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893) (BTAI)
BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893)
Date: Jan. 15, 2025 · CIK: 0001720893 · Accession: 0000000000-25-000439
AI Filing Summary & Sentiment
File numbers found in text: 333-284224
Letter
January 15, 2025 Vimal Mehta Chief Executive Officer BioXcel Therapeutics, Inc. 780 East Main Street Branford, CT 06405 Re:BioXcel Therapeutics, Inc. Registration Statement on Form S-3 Filed January 10, 2025 File No. 333-284224 Dear Vimal Mehta: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Emily Johns
Show Raw Text
January 15, 2025
Vimal Mehta
Chief Executive Officer
BioXcel Therapeutics, Inc.
780 East Main Street
Branford, CT 06405
Re:BioXcel Therapeutics, Inc.
Registration Statement on Form S-3
Filed January 10, 2025
File No. 333-284224
Dear Vimal Mehta:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Emily Johns